Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease

December 23, 2025 UCBN News, Syndication Comments Off on Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease

BOULDER, Colo.–(BUSINESS WIRE)–Enveda, a multi-asset clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ENV-6946. Following this clearance, Enveda has initiated a Phase 1 clinical trial for ENV-6946, a first-in-class oral small molecule for the treatment of Inflamm
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Related Articles

No Picture
News

A Celebration of Loyalty

August 22, 2022 UCBN News Comments Off on A Celebration of Loyalty

On Aug. 18, alumni, friends, faculty and staff gathered on campus for the fifth Loyal Benefactor Celebration. This event honors those who make ongoing annual gifts to support the university, those who have included the […]